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A case of branch retinal vein occlusion after vitrectomy 
in a patient receiving tamoxifen
Satoshi IWAASA,  Miwa TANAKA,  Kenichi MIZUKAWA,  Toshiya MIKI,  Junichi KIRYU
Depatment of Ophthalmology 1, Kawasaki Hospital, Kawasaki Medical School, 
577 Matsushima, Kurashiki, 701-0192, Japan
ABSTRACT   Tamoxifen is often used for treating breast cancer. However, tamoxifen-induced 
ocular complications are very rare. We will report on a case of branch retinal vein occlusion 
(BRVO) associated with tamoxifen use. A fifty-one year old female was receiving peroral 
tamoxifen with daily doses of 20 mg following surgery for breast cancer. A macular hole was 
detected in her left eye two years later and vitreous surgery was performed. It was observed 
that there was bleeding from the inferior arcade vessels after inducing the posterior vitreous 
detachment. Hemostasis of the vein was performed by raising the intraocular perfusion pressure 
and by compression of the bleeding site. The macular hole was closed on a postoperative day. 
A fundus examination revealed that the left branch retinal vein occlusion started bleeding fifteen 
days after the surgery. There was almost no change compared with preoperative visual acuity, 
but optical coherence tomography (OCT) showed a macular edema. Therefore, intravitreal 
injections of  bevacizumab and tamoxifen therapy were discontinued. Although BRVO is rare, 
ophthalmologists should be alerted to this type of ocular side effect.
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